Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes

Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes Purpose of Review Immune dysregulation is a defining feature of myelodysplastic syndromes (MDS). Recently, several studies have further defined the complex role of immune alterations within MDS. Herein, we will summarize some of these findings and discuss the therapeutic strategies currently in development. Recent Findings Immune alterations in MDS are complex, heterogeneous, and intertwined with clonal hematopoiesis and stromal cell dysfunction. Inflammation in MDS proceeds as a vicious cycle, mediated in large part by secreted factors, which induce cell death and activate innate immune signaling. Therapeutic targeting of this variable immune dysregulation has led to modest responses thus far, but incorporation of the growing repertoire of immunotherapy brings new potential for improved outcomes. Summary The immune milieu is variable across the spectrum of MDS subtypes, with a changing balance of inflammatory and suppressive cellular forces from low- to high-risk disease. . . . . Keywords Myelodysplastic syndromes Inflammation Immune dysregulation Bone marrow microenvironment Immunotherapy Introduction Preclinical and clinical studies have shown that chronic or un- resolved inflammation disrupts immune function and alters the Myelodysplastic syndromes (MDS) constitute a heterogeneous bone marrow microenvironment, thus contributing to disease group of clonal bone marrow neoplasms defined by hemato- initiation and progression (Fig. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hematologic Malignancy Reports Springer Journals

Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes

Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/disordered-immune-regulation-and-its-therapeutic-targeting-in-onDPv7NzzI

References (104)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
ISSN
1558-8211
eISSN
1558-822X
DOI
10.1007/s11899-018-0463-9
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review Immune dysregulation is a defining feature of myelodysplastic syndromes (MDS). Recently, several studies have further defined the complex role of immune alterations within MDS. Herein, we will summarize some of these findings and discuss the therapeutic strategies currently in development. Recent Findings Immune alterations in MDS are complex, heterogeneous, and intertwined with clonal hematopoiesis and stromal cell dysfunction. Inflammation in MDS proceeds as a vicious cycle, mediated in large part by secreted factors, which induce cell death and activate innate immune signaling. Therapeutic targeting of this variable immune dysregulation has led to modest responses thus far, but incorporation of the growing repertoire of immunotherapy brings new potential for improved outcomes. Summary The immune milieu is variable across the spectrum of MDS subtypes, with a changing balance of inflammatory and suppressive cellular forces from low- to high-risk disease. . . . . Keywords Myelodysplastic syndromes Inflammation Immune dysregulation Bone marrow microenvironment Immunotherapy Introduction Preclinical and clinical studies have shown that chronic or un- resolved inflammation disrupts immune function and alters the Myelodysplastic syndromes (MDS) constitute a heterogeneous bone marrow microenvironment, thus contributing to disease group of clonal bone marrow neoplasms defined by hemato- initiation and progression (Fig.

Journal

Current Hematologic Malignancy Reports – Springer Journals

Published: Jun 22, 2018

There are no references for this article.